Teva and Allergan Reach Proposed Settlements Totaling $6.6 Billion over Opioid Allegations

Lori Kalani, Bernard Nash
Cozen O'Connor
Contact
LinkedIn
Facebook
X
Send
Embed

Cozen O'Connor

  • A group of 8 AGs reached agreements with Teva Pharmaceutical Industries Ltd. and Allergan Limited, as well as their respective affiliated entities, to resolve allegations regarding the companies’ roles in contributing to the nationwide opioid crisis.
  • The Teva and Allergan settlements, the latest in a series of settlements between AGs and manufacturers, distributors, and retailers of opioids, resolve allegations that the companies illegally marketed opioid medications that they manufactured and failed to maintain effective diversion controls.
  • Under the terms of the settlements, Teva is required to pay $4.24 billion and Allergan is required to pay $2.37 billion, inclusive of amounts the companies have paid to previously settling states. Teva will provide up to $1.2 billion in generic naloxone—an opioid antagonist that rapidly reverses the effects of an overdose. Allergan and Teva are prohibited from promoting opioid products or engaging in opioid-related lobbying, among other things. Allergan, which does not currently manufacture any opioid products, is prohibited from manufacturing or selling them in the future.
  • Another 35 states, as well as the District of Columbia and several U.S. territories, will have thirty days from the date of the agreements to decide whether or not to join in the proposed settlement.
Send Print Report

DISCLAIMER: Because of the generality of this update, the information provided herein may not be applicable in all situations and should not be acted upon without specific legal advice based on particular situations.

© Cozen O'Connor | Attorney Advertising

Written by:

Cozen O'Connor
Cozen O'Connor
Contact
more
less

Cozen O'Connor on:

Reporters on Deadline

"My best business intelligence, in one easy email…"

Your first step to building a free, personalized, morning email brief covering pertinent authors and topics on JD Supra:
Sign Up Log in
*By using the service, you signify your acceptance of JD Supra's Privacy Policy.
Custom Email Digest
- hide
- hide